Introduction: Within the ventromedial hypothalamus (VMH), glucose inhibitory (GI) neurons sense hypoglycaemia while glucose excitatory (GE) neurons sense hyperglycaemia to initiate counter control mechanisms under normal conditions. However, potential electrophysiological alterations of these two neuronal types in vivo in insulin‐resistant states have never been simultaneously fully documented. Further, the anti‐diabetic effect of dopamine agonism on this VMH system under insulin resistance has not been studied.Methods: This study examined the impact of a high‐fat diet (HFD) on in vivo electrophysiological recordings from VMH GE and GI neurons and the ability of circadian‐timed dopamine agonist therapy to reverse any adverse effect of the HFD on such VMH activities and peripheral glucose metabolism.Results: HFD significantly inhibited VMH GE neuronal electrophysiological response to local hyperglycaemia (36.3%) and augmented GI neuronal excitation response to local hypoglycaemia (47.0%). Bromocriptine (dopamine agonist) administration at onset of daily activity (but not during the daily sleep phase) completely reversed both VMH GE and GI neuronal aberrations induced by HFD. Such timed treatment also normalized glucose intolerance and insulin resistance. These VMH and peripheral glucose metabolism effects of circadian‐timed bromocriptine may involve its known effect to reduce elevated VMH noradrenergic activity in insulin‐resistant states as local VMH administration of norepinephrine was observed to significantly inhibit VMH GE neuronal sensing of local hyperglycaemia in insulin‐sensitive animals on regular chow diet (52.4%).Conclusions: HFD alters VMH glucose sensing in a manner that potentiates hyperglycaemia and this effect on the VMH can be reversed by appropriately circadian‐timed dopamine agonist administration.
Consumption of the “westernized diet” (WD) of high fat and sucrose promotes the development of hepatic insulin resistance and metabolic syndrome (MS). This diet is well known to reduce brain dopamine activity and stimulate chronic over-activation of the sympathetic nervous system that potentiate liver insulin resistance by as yet unknown mechanisms. This study evaluated the effect of circadian-timed bromocriptine, a sympatholytic dopamine agonist, to reverse the adverse effects of the WD on glucose tolerance and liver expression of several genes involved in hepatic aspects of insulin sensitivity including lipid balance, inflammation and ER stress. Female Sprague-Dawley rats were maintained on a WD of high fat (40% by kcal/g) and sucrose (29% by kcal/g) for 4 weeks and then administered BC (7.5 mg/kg) or vehicle (N =10/group) at the onset of daily waking for an additional 10 weeks while maintained on WD to study end when a GTT (3g/kg glucose) was performed and 5 days later when animals were sacrificed for analyses of hepatic genes (via PCR) involved in insulin sensitivity. A regular chow fed group (N=10) served as positive control. BC treatment reduced the GTT glucose AUC by 39% vs. controls (P<0.001) without change in the insulin AUC and reduced body fat level by 35% (P= 0.01) without change in feeding vs. controls. BC also reduced hepatic gene transcripts for fatty acid oxidation - PPARa and CPT1A by 35 and 48%, respectively (P<0.03), for lipid synthesis - DGAT2 by 20% (P<0.04), and for inflammation and ER stress - monocyte chemoattractant protein 1 and C/EBP homologous protein by 40 and 47% (P<0.05), respectively, vs. controls, all to levels observed in regular chow fed rats. This study demonstrated that bromocriptine can reverse the adverse effects of WD on hepatic lipid, inflammation, and ER stress gene expression pathways that promote hepatic insulin resistance and MS. Disclosure: Y. Zhang: Employee; Self; VeroScience LLC. M. Ezrokhi: Employee; Self; VeroScience LLC. N. Cominos: Employee; Self; VeroScience LLC. A.H. Cincotta: Employee; Self; VeroScience LLC.
The melatonin receptors hMT 1 and hMT 2 are differentially desensitized by melatonin (MLT) which contributes to temporally regulated MLT signaling. At physiological concentrations (~500 pM), MLT functionally desensitizes and internalizes hMT 2 receptors. hMT 1 Receptors desensitize but do not internalize by supraphysiological concentration of MLT. The present study examined the PDZ binding motifs at carboxyl termini of hMT 1 (VDSV) and hMT 2 (ADAL) in regulating receptor membrane expression in HEK cells. Deletion of VDSV and ADAL motifs reduced 2‐[I 125 ]‐iodomelatonin (100 pM) binding to the receptors (fmol/mg protein: 1112 ± 154 vs 19 ± 2.6 for hMT 1 ; 694 ± 152 vs 2.1 ± 1.3 for hMT 2 ), and diminished their membrane localization assessed by confocal microscopy. Interestingly, their differential desensitization by MLT were preserved in hMT 1 PDZ and hMT 2 PDZ. MLT reduced 2‐[I 125 ]‐iodomelatonin binding in cells expressing hMT 2 PDZ (2.1± 1.3 vs 0.3 ± 0.3 fmole/mg protein), but not hMT 1 PDZ. This is consistent with previous results that switching hMT 1 and hMT 2 carboxyl termini does not alter their characteristic desensitization/internalization responses to MLT. In conclusion, C‐terminal PDZ binding motif is required for hMT 1 and hMT 2 membrane expression and that the molecular determinant(s) for their differential desensitization by MLT is not localized at carboxyl terminus. Supported by MH 42922 to MLD .